Last reviewed 2026-05-13 · How we verify

BBV154 Intranasal Vaccine

BBV154 is an intranasal recombinant vaccine that stimulates mucosal and systemic immune responses against SARS-CoV-2 by delivering viral antigens directly to respiratory tract tissues.

BBV154 is an intranasal recombinant vaccine that stimulates mucosal and systemic immune responses against SARS-CoV-2 by delivering viral antigens directly to respiratory tract tissues. Used for COVID-19 prevention (intranasal booster or primary series).

At a glance

Mechanism of action

The vaccine uses a recombinant viral vector platform administered intranasally to induce both mucosal (IgA) and systemic (IgG) antibody responses, as well as T-cell immunity. By targeting the respiratory mucosa directly, it aims to provide protection at the site of viral entry and establish broader immune memory against COVID-19.

Approved indications

• COVID-19 prevention (intranasal booster or primary series)

Common side effects

• Headache
• Nasal congestion
• Fatigue
• Myalgia

Key clinical trials

• BBV152/BBV154 Heterologus Prime-Boost Study (PHASE2)
• Phase 3 Study to Evaluate Immunogenicity and Safety of BBV154 Booster Dose (PHASE3)
• Phase III Study of BBV154 Intranasal Vaccine in Healthy Volunteers (PHASE3)
• Safety and Immunogenicity of an Intranasal SARS-CoV-2 Vaccine (BBV154) for COVID-19 (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• BBV154 Intranasal Vaccine CI brief — competitive landscape report
• BBV154 Intranasal Vaccine updates RSS · CI watch RSS
• Bharat Biotech International Limited portfolio CI